NICE announces start of review of nusinersen Managed Access Agreement (MAA)

Review will assess whether new evidence has become available to support change in treatment eligibility criteria; specifically, whether people with type III spinal muscular atrophy who are unable to walk can benefit from treatment and therefore should be included in MAA.

Source:

National Institute for Health and Care Excellence